Scott Schuetze, MD
Enriched profileClinical Professor of Internal Medicine, University of Michigan Medical School · University of Michigan Medical School
Scott Schuetze is Clinical Professor of Internal Medicine, University of Michigan Medical School at University of Michigan Medical School. OpenAlex indexes 277 publications with 20,592 citations (h-index 60); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 13 Oct 2026
Scott Schuetze, MD, PHD, is Clinical Professor of Internal Medicine, University of Michigan Medical School. The public record shows 277 publications with 20,592 citations (h-index 60), centered on Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Vascular Tumors and Angiosarcomas. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 5 companies, 5 NIH-funded awards (2005–2026).
- Most recent indexed publication: 2026 · Nature medicine
- Top research focus: Sarcoma Diagnosis and Treatment
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 13 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 133.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
Sponsor: National Cancer Institute (NCI)
- Metastatic Leiomyosarcoma Biomarker Protocol
Sponsor: University of Michigan Rogel Cancer Center
Industry payments
Updated 13 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Deciphera Pharmaceuticals Inc.Program year20246 payments
- Boehringer Ingelheim International GmbHProgram year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
33.6%Kinase inhibitor33.6%Imatinib Mesylate100%Part D≥15 patientsMetabolism & gastrointestinal
20.6%Serotonin-3 Receptor Antagonist20.6%Ondansetron Hcl67%Ondansetron Odt33%Part D<11 patientsSensory organs
16.1%Corticosteroid16.1%Dexamethasone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 13 Oct 2026
5 NIH research awards on record, funded 2005–2026 per NIH RePORTER. The latest:
- Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatment
University of Michigan at Ann Arbor
FY2026$2,367,476P50CA272170 - Early Phase Clinical Cancer Prevention Consortium
University of Michigan at Ann Arbor
FY2026$1,408,123UG1CA242632
Congress activity
Updated 13 Oct 2026
82 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma.
ASCO Annual Meeting
ASCO2026Co-author - Pooled analyses of clinical outcomes with afamitresgene autoleucel (afami-cel) in metastatic synovial sarcoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 13 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.
Nature medicine
Clinical Trial2026 - A Phase II Multicenter Trial of Trabectedin in Combination with Olaparib in Patients with Advanced Unresectable or Metastatic Sarcoma.
Clinical cancer research
Clinical Trial2025 - Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Journal of clinical oncology
Clinical Trial2025 - A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01
- 02NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal TumorsArticle1,223 citations2010
- 03Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyArticle1,168 citations2022
- 04Integrative clinical genomics of metastatic cancerArticle937 citations2017
- 05
Network
Updated 13 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 13 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/scott-schuetze-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Scott-Schuetze
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
ctos2024.eventscribe.net/ajaxcalls/posterPresenterInfo.asp
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ctos2024.eventscribe.net ↗ - Other
curesarcoma.org/people/scott-michael-schuetze-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curesarcoma.org ↗ - Other
medschool.umich.edu/profile/2279/scott-m-schuetze
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umich.edu ↗ - Other
rogelcancercenter.org/news/archive/u-m-lead-multi-site-12m-grant-study-rare-type-sarcoma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rogelcancercenter.org ↗ - Other
uofmhealth.org/profile/1003/scott-michael-schuetze-md-phd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uofmhealth.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 13 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Oregon Health & Science University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗ - PhD
Biochemistry and Molecular Biology, Oregon Health & Science University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗ - BA
Biology, Rice University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗ - Board certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗
Editorial & leadership roles
journal and society appointments- Member
Medical Advisory Board, Sarcoma Foundation of America
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →curesarcoma.org ↗ - Member
National Comprehensive Cancer Network Soft Tissue Sarcoma Treatment Guidelines Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ctos2024.eventscribe.net ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umich.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umich.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umich.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →curesarcoma.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bertram Pitt, MD
University of Michigan Medical School
Anna Lok, MD
University of Michigan Medical School
Roger Albin, MD
University of Michigan Medical School
Meilan Han, MD
University of Michigan Medical School
George Demetri, MD
Dana-Farber Cancer Institute; Professor of Medicine
Richard Gorlick, MD
The University of Texas MD Anderson Cancer Center
William Tap, MD
Memorial Sloan Kettering Cancer Center
Steven Dubois, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School